Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PRECIGEN, INC.PGEN · Entity 4356 | President and CEO | August 23, 2026 | August 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PRECIGEN, INC.
Report date August 23, 2026 · Filed August 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,779,521 |
Ending reported balance
After 2026-08-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-23 · Exercise / conversion · Acquired 20,833 · Balance 3,789,705 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. Row 2 · 2026-08-23 · Tax withholding · Disposed 10,184 · Balance 3,779,521 F2: Represents the number of shares of Precigen common stock withheld by the Issuer to satisfy income tax withholding obligations in connection with the settlement of the RSUs. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 229,167 |
Reported balance
After 2026-08-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-23 · Exercise / conversion · Disposed 20,833 · Balance 229,167 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. F3: Represents 1/24 of the RSUs granted on June 26, 2025 that vested on August 23, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock.
F2: Represents the number of shares of Precigen common stock withheld by the Issuer to satisfy income tax withholding obligations in connection with the settlement of the RSUs.
F3: Represents 1/24 of the RSUs granted on June 26, 2025 that vested on August 23, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Kinnate Biopharma Inc.
Report date April 03, 2024 · Filed April 05, 2024
Section 16 reporting ended · disclosed 2024-04-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.38 · Expires 2031-06-24 | Direct | 0 |
Reported balance
After 2024-04-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-04-03 · Disposition to issuer · Disposed 40,501 · Balance 0 F1: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.48 · Expires 2033-06-12 | Direct | 0 |
Reported balance
After 2024-04-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-04-03 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.38 · Expires 2032-06-13 | Direct | 0 |
Reported balance
After 2024-04-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-04-03 · Disposition to issuer · Disposed 20,250 · Balance 0 F1: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2020 Filed Jan 3, 2020 21:32 UTC | PRECIGEN, INC. XON · Entity 4356 | SaleCommon Stock | 4,830 | $5.60 | $27,048.00 |
DisclosureSEC source: 0001123292-20-000042 · edgar.xml · nonDerivative · entry 2 Sabzevari Helen · CIK 0001724195 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,187 F2 · kind: This sale was effected pursuant to the terms of a 10b5-1 plan adopted by the reporting person and was made in order to pay the tax liability arising from the vesting of restricted stock units. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:16 UTC | PRECIGEN, INC. XON · Entity 4356 | Exercise / conversionRestricted Stock Units · Derivative | 9,766 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-20-000069 · edgar.xml · derivative · entry 3 Sabzevari Helen · CIK 0001724195 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,531 Underlying: Common Stock · 9,766 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. F3 · derivative.exercise_date: The restricted stock units were granted on January 2, 2018, and the remaining restricted stock units vest in two equal annual installments on each of January 2, 2021 and 2022. F3 · derivative.expiration_date: The restricted stock units were granted on January 2, 2018, and the remaining restricted stock units vest in two equal annual installments on each of January 2, 2021 and 2022. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:16 UTC | PRECIGEN, INC. XON · Entity 4356 | Exercise / conversionCommon Stock | 9,766 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-20-000069 · edgar.xml · nonDerivative · entry 1 Sabzevari Helen · CIK 0001724195 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,953 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 21:32 UTC | PRECIGEN, INC. XON · Entity 4356 | Exercise / conversionRestricted Stock Units · Derivative | 14,340 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-20-000042 · edgar.xml · derivative · entry 3 Sabzevari Helen · CIK 0001724195 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,340 Underlying: Common Stock · 14,340 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. F3 · derivative.exercise_date: The restricted stock units were granted on April 9, 2019, and the remaining restricted stock units vest on March 31, 2020. F3 · derivative.expiration_date: The restricted stock units were granted on April 9, 2019, and the remaining restricted stock units vest on March 31, 2020. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 21:32 UTC | PRECIGEN, INC. XON · Entity 4356 | Exercise / conversionCommon Stock | 14,340 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-20-000042 · edgar.xml · nonDerivative · entry 1 Sabzevari Helen · CIK 0001724195 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,017 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. Read SEC document |
| October 01, 2019 Filed Oct 2, 2019 21:25 UTC | PRECIGEN, INC. XON · Entity 4356 | SaleCommon Stock | 5,005 | $5.50 | $27,506.98 |
DisclosureSEC source: 0001123292-19-001189 · edgar.xml · nonDerivative · entry 2 Sabzevari Helen · CIK 0001724195 · President, Precigen, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,677 F2 · kind: This sale was effected pursuant to the terms of a 10b5-1 plan adopted by the reporting person and was made in order to pay the tax liability arising from the vesting of restricted stock units. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 21:25 UTC | PRECIGEN, INC. XON · Entity 4356 | Exercise / conversionRestricted Stock Units · Derivative | 14,341 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-19-001189 · edgar.xml · derivative · entry 3 Sabzevari Helen · CIK 0001724195 · President, Precigen, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,680 Underlying: Common Stock · 14,341 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. F3 · derivative.exercise_date: The restricted stock units were granted on April 9, 2019, and the remaining restricted stock units vest in two equal quarterly installments on each of December 31, 2019 and March 31, 2020. F3 · derivative.expiration_date: The restricted stock units were granted on April 9, 2019, and the remaining restricted stock units vest in two equal quarterly installments on each of December 31, 2019 and March 31, 2020. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 21:25 UTC | PRECIGEN, INC. XON · Entity 4356 | Exercise / conversionCommon Stock | 14,341 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-19-001189 · edgar.xml · nonDerivative · entry 1 Sabzevari Helen · CIK 0001724195 · President, Precigen, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,682 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. Read SEC document |
| July 18, 2019 Filed Jul 19, 2019 21:21 UTC | PRECIGEN, INC. XON · Entity 4356 | SaleCommon Stock | 8,484 | $7.47 | $63,377.18 |
DisclosureSEC source: 0001123292-19-001013 · edgar.xml · nonDerivative · entry 2 Sabzevari Helen · CIK 0001724195 · President, Precigen, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,341 F2 · kind: This sale was effected pursuant to the terms of a 10b5-1 plan adopted by the reporting person and was made in order to pay the tax liability arising from the vesting of restricted stock units. Read SEC document |
| July 17, 2019 Filed Jul 19, 2019 21:21 UTC | PRECIGEN, INC. XON · Entity 4356 | Exercise / conversionRestricted Stock Units · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-19-001013 · edgar.xml · derivative · entry 3 Sabzevari Helen · CIK 0001724195 · President, Precigen, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. F3 · derivative.exercise_date: The restricted stock units were granted on March 28, 2018, and the remaining restricted stock units vest in two equal annual installments on each of July 17, 2020 and July 17, 2021. F3 · derivative.expiration_date: The restricted stock units were granted on March 28, 2018, and the remaining restricted stock units vest in two equal annual installments on each of July 17, 2020 and July 17, 2021. Read SEC document |
| July 17, 2019 Filed Jul 19, 2019 21:21 UTC | PRECIGEN, INC. XON · Entity 4356 | Exercise / conversionCommon Stock | 25,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-19-001013 · edgar.xml · nonDerivative · entry 1 Sabzevari Helen · CIK 0001724195 · President, Precigen, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,825 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 23:12 UTC | PRECIGEN, INC. XON · Entity 4356 | SaleCommon Stock | 4,822 | $7.76 | $37,418.72 |
DisclosureSEC source: 0001123292-19-000964 · edgar.xml · nonDerivative · entry 2 Sabzevari Helen · CIK 0001724195 · President, Precigen, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,825 F2 · kind: This sale was effected pursuant to the terms of a 10b5-1 plan adopted by the reporting person and was made in order to pay the tax liability arising from the vesting of restricted stock units. Read SEC document |
| June 30, 2019 Filed Jul 2, 2019 23:12 UTC | PRECIGEN, INC. XON · Entity 4356 | Exercise / conversionRestricted Stock Units · Derivative | 14,341 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-19-000964 · edgar.xml · derivative · entry 3 Sabzevari Helen · CIK 0001724195 · President, Precigen, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,021 Underlying: Common Stock · 14,341 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. F3 · derivative.exercise_date: The restricted stock units were granted on April 9, 2019, and the remaining restricted stock units vest in three equal quarterly installments on each of September 30, 2019, December 31, 2019 and March 31, 2020. F3 · derivative.expiration_date: The restricted stock units were granted on April 9, 2019, and the remaining restricted stock units vest in three equal quarterly installments on each of September 30, 2019, December 31, 2019 and March 31, 2020. Read SEC document |
| June 30, 2019 Filed Jul 2, 2019 23:12 UTC | PRECIGEN, INC. XON · Entity 4356 | Exercise / conversionCommon Stock | 14,341 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-19-000964 · edgar.xml · nonDerivative · entry 1 Sabzevari Helen · CIK 0001724195 · President, Precigen, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,647 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. Read SEC document |
| April 09, 2019 Filed Apr 12, 2019 01:44 UTC | PRECIGEN, INC. XON · Entity 4356 | GrantRestricted Stock Units · Derivative | 57,362 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-19-000633 · edgar.xml · derivative · entry 1 Sabzevari Helen · CIK 0001724195 · President, Precigen, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,362 Underlying: Common Stock · 57,362 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. F2 · derivative.exercise_date: The restricted stock units vest in four equal quarterly installments beginning June 30, 2019. F2 · derivative.expiration_date: The restricted stock units vest in four equal quarterly installments beginning June 30, 2019. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 22:31 UTC | PRECIGEN, INC. XON · Entity 4356 | GrantRestricted Stock Units · Derivative | 56,891 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-19-000206 · edgar.xml · derivative · entry 1 Sabzevari Helen · CIK 0001724195 · President, Precigen, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,666 Underlying: Common Stock · 56,891 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 4, 2020. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 4, 2020. Read SEC document |
| January 04, 2019 Filed Jan 9, 2019 01:07 UTC | PRECIGEN, INC. XON · Entity 4356 | GrantRestricted Stock Units · Derivative | 13,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-19-000130 · edgar.xml · derivative · entry 2 Sabzevari Helen · CIK 0001724195 · President, Precigen, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,775 Underlying: Common Stock · 13,775 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 4, 2020. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 4, 2020. Read SEC document |
| January 04, 2019 Filed Jan 9, 2019 01:07 UTC | PRECIGEN, INC. XON · Entity 4356 | GrantCommon Stock | 13,774 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-19-000130 · edgar.xml · nonDerivative · entry 1 Sabzevari Helen · CIK 0001724195 · President, Precigen, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,306 F1 · price: These shares of common stock resulted from the grant and immediate vesting of restricted stock units that were issued as a portion of the reporting person's 2018 incentive compensation. Read SEC document |
| January 03, 2019 Filed Jan 4, 2019 23:46 UTC | PRECIGEN, INC. XON · Entity 4356 | SaleCommon Stock | 3,832 | $7.07 | $27,094.16 |
DisclosureSEC source: 0001123292-19-000084 · edgar.xml · nonDerivative · entry 2 Sabzevari Helen · CIK 0001724195 · President, Precigen, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,532 F2 · kind: This sale was effected pursuant to the terms of a 10b5-1 plan adopted by the reporting person and was made in order to pay the tax liability arising from the vesting of restricted stock units. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 23:46 UTC | PRECIGEN, INC. XON · Entity 4356 | Exercise / conversionRestricted Stock Units · Derivative | 9,766 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-19-000084 · edgar.xml · derivative · entry 3 Sabzevari Helen · CIK 0001724195 · President, Precigen, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,297 Underlying: Common Stock · 9,766 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. F3 · derivative.exercise_date: The restricted stock units were granted on January 2, 2018, and the remaining restricted stock units vest in three equal annual installments on each of January 2020, 2021 and 2022. F3 · derivative.expiration_date: The restricted stock units were granted on January 2, 2018, and the remaining restricted stock units vest in three equal annual installments on each of January 2020, 2021 and 2022. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 23:46 UTC | PRECIGEN, INC. XON · Entity 4356 | Exercise / conversionCommon Stock | 9,766 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-19-000084 · edgar.xml · nonDerivative · entry 1 Sabzevari Helen · CIK 0001724195 · President, Precigen, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,364 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. Read SEC document |
| July 18, 2018 Filed Jul 19, 2018 22:03 UTC | PRECIGEN, INC. XON · Entity 4356 | SaleCommon Stock | 8,402 | $14.54 | $122,165.08 |
DisclosureSEC source: 0001123292-18-000869 · edgar.xml · nonDerivative · entry 2 Sabzevari Helen · CIK 0001724195 · President, Precigen, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,598 F2 · kind: This sale was effected pursuant to the terms of a 10b5-1 plan adopted by the reporting person and was made in order to pay the tax liability arising from the vesting of restricted stock units. Read SEC document |
| July 17, 2018 Filed Jul 19, 2018 22:03 UTC | PRECIGEN, INC. XON · Entity 4356 | Exercise / conversionRestricted Stock Units · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-18-000869 · edgar.xml · derivative · entry 3 Sabzevari Helen · CIK 0001724195 · President, Precigen, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. F3 · derivative.exercise_date: The restricted stock units were granted on March 28, 2018, and the remaining restricted stock units vest in three equal annual installments on each of July 17, 2019, 2020 and 2021. F3 · derivative.expiration_date: The restricted stock units were granted on March 28, 2018, and the remaining restricted stock units vest in three equal annual installments on each of July 17, 2019, 2020 and 2021. Read SEC document |
| July 17, 2018 Filed Jul 19, 2018 22:03 UTC | PRECIGEN, INC. XON · Entity 4356 | Exercise / conversionCommon Stock | 25,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-18-000869 · edgar.xml · nonDerivative · entry 1 Sabzevari Helen · CIK 0001724195 · President, Precigen, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. Read SEC document |
| March 28, 2018 Filed Apr 5, 2018 20:56 UTC | PRECIGEN, INC. XON · Entity 4356 | GrantRestricted Stock Units · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-18-000620 · edgar.xml · derivative · entry 1 Sabzevari Helen · CIK 0001724195 · President, Precigen, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning July 17, 2018. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning July 17, 2018. Read SEC document |
| January 02, 2018 Filed Jan 9, 2018 01:21 UTC | PRECIGEN, INC. XON · Entity 4356 | GrantRestricted Stock Units · Derivative | 39,063 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-18-000105 · edgar.xml · derivative · entry 1 Sabzevari Helen · CIK 0001724195 · President, Precigen, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,063 Underlying: Common Stock · 39,063 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 2, 2019. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 2, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.